Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal Phase 2 Trial of Ponatinib in Refractory CML and Ph+ ALL
KCT0000516Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by ARIAD Pharmaceuticals, Inc.. Started Jan 2011; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on KCT0000516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000516.